Pharmacovigilance Translation Services and Automation

When patient safety is on the line, every word matters. Our streamlined process translates your critical pharmacovigilance documents with unmatched accuracy, speed, and compliance, so you can focus on what matters most—protecting patient safety worldwide.

Contact Us
translation services in patient services

Achieve Global Compliance with Speed and Precision

  • Icon

Industry-Leading Technology

Leverage accurate translations using neural machine translation, secure client portals, and automated quality checks.

  • Icon

Efficient Translation Process

Maximize speed and precision with AI-powered initial translations followed by expert linguistic evaluation.

  • Icon Outbound Recruitment

Commitment to Quality

Guarantee quality with dual-review processes and cutting-edge automation to meet the highest global standards.

  • Icon

Comprehensive Safety Solutions

Go beyond translation with multilingual case triage, database reporting, literature monitoring, and redaction.

Accelerate Your Drug Safety Reporting

Deliver more reliable translations for all critical safety documents quickly. We make sure your documentation is precise and ready for submission.

Pharmacovigilance Document Translations

Translate all of your pharmacovigilance and drug safety materials with a global team of expert linguists. You can rely on TransPerfect for nuanced translations of risk management plans, clinical trial documents, regulatory submissions, and safety communications, DSURS, PADERs, PSURs, AERs and more.

AI-Powered Translation Efficiency

Accelerate pharmacovigilance translation with GlobalLink, TransPerfect’s groundbreaking artificial intelligence platform. GlobalLink adapts to medical terminology and context, recalls previously approved translations from translation memory for speed and consistency, flags discrepancies for review and provides expert linguistic refinement.

Regulatory Compliance Expertise

Meet the stringent requirements of the FDA, EMA, PMDA, and other regulatory authorities with translations aligned to global standards. Our expert linguists adhere to strict ISO 9001, ISO 18587, and ISO 17100 certification standards. All of our processes align with ASTM F2575-06, GDPR, ERES, GxP, 21 CFR Part 11, Annex 11, HITRUST, and other global pharma, biotech, and medical device compliance requirements.

Faster Translation and Cost Savings with AI

Leveraging AI for fast, cost-effective translations allows you to meet multilingual reporting requirements while reducing overall cycle times by 40%. A global team of on-demand translation experts provides an extra layer of quality assurance. For additional information on how to streamline the process, visit our Pharmacovigilance Solutions page.

Trusted by Life Sciences Organizations Big and Small

Pharmacovigilance Document Translations

Accurate translations of pharmacovigilance documents are essential for maintaining regulatory adherence and ensuring safety. With expertise in translating key documents across the product lifecycle, from Pharmacovigilance System Master File (PSMF) documents through to commercialization communications. Our automated translations meet the specific requirements of regulatory agencies such as the FDA, EMA, and others. This system also includes a case triage process for timely categorization and prioritization of adverse event reports.

Popular pharmacovigilance and drug safety translation projects include:

Adverse Event and Safety Reporting

  • Case Report Forms (CRFs)
  • Individual Case Safety Reports (ICSRs)
  • Adverse Event Reports (AERs)
  • Serious Adverse Event Reports (SAE Reports)
  • Suspected Unexpected Serious Adverse Reactions (SUSARs)
  • Periodic Safety Update Reports (PSURs)
  • Periodic Adverse Drug Experience Reports (PADERs)
  • Signal Detection and Management Reports
  • Medication Error Reports
  • Vaccination Adverse Event Reports
  • Aggregate Signal Detection Summaries

Database Reporting and Case Management

Regulatory Submissions and Approvals

  • New Drug Applications (NDAs)
  • Investigational New Drug Safety Report (INDSRs)
  • Investigational New Drug Reporting (INDRs)
  • Pharmacovigilance Agreements (PVAs)
  • Risk Evaluation and Mitigation Strategies (REMS)
  • Development Safety Update Reports (DSURs)
  • Post-Marketing Surveillance Reports
  • Post-Authorization Safety Studies (PASS)
  • Health Authority Queries and Responses
  • Common Technical Document (CTD) Sections
  • Orphan Drug Designation Applications
  • Variations and Amendments

Risk Management and Mitigation

  • Pharmacovigilance Risk Management Plans (RMPs)
  • Benefit-Risk Assessment Reports
  • Field Safety Corrective Actions (FSCA) Notices
  • Safety Data Exchange Agreements (SDEAs)
  • Drug Safety Compliance Audit Reports
  • Post-Marketing Commitment Reports
  • Corrective and Preventative Action (CAPA) Reports
  • Safety Signal Assessment Reports

Clinical Documentation and Reporting

  • Clinical Study Reports (CSRs)
  • Nonclinical Study Reports
  • Aggregate Reports
  • Summary of Product Characteristics (SmPCs)
  • Protocol Deviation Reports
  • Investigator Brochures (IBs)
  • Clinical Trial Protocols

Patient and Healthcare Communications

  • Product Information Leaflets
  • Patient Safety Information
  • Direct Healthcare Professional Communications (DHCPs)
  • Dear Health Care Provider Letters (DHCP Letters)
  • Medication Guides (MedGuides)
  • Safety Narratives
  • Public Safety Announcements (PSAs)
  • Educational Materials for Healthcare Professionals
  • FAQs on Adverse Drug Reactions

Operational and Procedural Documentation

  • Global Pharmacovigilance Procedural Documents
  • Biological Product Deviation Reports (BPDRs)
  • Quality Defect Reports
  • Medical Device Adverse Event Reports
  • Local Safety Officer (LSO) Communications
  • Pharmacovigilance SOPs (Standard Operating Procedures)
  • Training Manuals for Pharmacovigilance Teams
  • Vendor and Partner Compliance Reports

Frequently Asked Questions

How do you ensure translation accuracy?

Our dual-review process involves advanced neural machine learning paired with linguistic review by life sciences specialists. Dual-review ensures translations are accurate and meet regulatory compliance and industry standards.

How do you handle confidential information?

Your data will be secure as our team adheres to the highest industry standards. In addition to encrypted data handling, automated PII redaction is utilized to ensure that any personal or clinical data is carefully redacted in compliance with privacy laws (such as GDPR or HIPAA).

Can you handle large-volume projects with tight deadlines?

Yes, our global team of life sciences linguists leverages TransPerfect's proprietary translation management system to handle enterprise volumes with tight deadlines. Our infrastructure is designed to uphold the highest standards of quality, accuracy, and regulatory compliance, regardless of project size and timeline.

Do you offer support for post-market surveillance translations?

Yes, we provide comprehensive translation services for all phases of the product lifecycle, including post-market surveillance. All translations will be in compliance with global regulations for adverse event reporting, periodic safety update reports (PSURs), or risk management documentation.

What is your process for integrating translations into our existing pharmacovigilance systems?

Our translation services seamlessly integrate into your existing systems, including eTMF (electronic trial master files) and ePRO (electronic patient-reported outcome) systems. Our technical team works closely with yours for a smooth integration, reducing workflow disruptions and maximizing efficiency.

How do you handle updates or revisions to translated documents?

We provide revision support for any updates or changes to your documents, whether it’s a regulatory change or a modification to your safety reporting requirements.

News and Press Releases

XTalks | How MI, PV & Regulatory Collaborate on Signals, Labeling, Crisis Response and AI

Medical Information (MI), Pharmacovigilance (PV) and Regulatory Affairs (RA) each play distinct but deeply interconnected roles in ensuring that therapeutics are safe, accurately labeled and compliantly communicated to healthcare professionals and patients. Yet in practice, the boundaries between these functions are rarely clean; a safety signal surfaced through an MI inquiry can trigger a PV investigation, which in turn may prompt a label update, a Risk Management ...

XTalks | How MI, PV & Regulatory Collaborate on Signals, Labeling, Crisis Response and AI

LifeSci Talks COA Series | Nothing Remains the Same: Why Measures Have to Evolve

In this episode of LifeSci Talks, Mark Wade, Global Practice Leader at TransPerfect Life Sciences, sits down with RJ Wirth, CEO and Consulting Psychometrician at Vector Psychometric Group, to talk about why the measures we rely on are living things rather than fixed artifacts. ...

Regulatory Considerations for Paper COA Translations | What You Need to Know

Collecting data for a global clinical trial on paper COAs or managing a mixed-mode study that combines both paper and electronic formats means satisfying multiple regulatory bodies before a single patient enrolls. None of these entities operate on the same timeline or...

When "How Does the Patient Feel?" Became a Regulatory Question

For decades, clinical trials were built around things you could measure with a machine: tumor shrinkage on a scan, laboratory values, and disease progression. These hard, objective endpoints were the backbone of drug approval. The patient's own account of how they felt,...

XTalks | eCOA: Has It Lived Up to the Promise? A Realistic Assessment for Today's Trials

Despite two decades of technological advancement, the debate between paper and electronic clinical outcome assessments (eCOA) remains unresolved. This webinar revisits the assumptions that continue to shape data collection strategies and examines whether current practice reflects ...

SSCPs Are Not Labeling: Compliant AI Processes for Reduced Cost & Turnaround

In this fireside chat, TransPerfect Medical Device's President Marc Miller sits down with Dr. Keith Morel, VP of Regulatory Compliance at Qserve, to unpack a critical question facing medical device manufacturers under MDR: can you reduce the translation review process for ...

Top 10 Pharma Company Overhauls Global COA Program,Cutting Costs by 33% and Errors to Near Zero

Inconsistent standards, stretched timelines, and limited visibility were straining a top 10 pharma company's COA program. Discover how TransPerfect Life Sciences' centralization strategy delivered 99.7% accuracy, 40% less PM oversight, and 33% cost savings across the ...

Ready to translate your critical pharmacovigilance documents?

Discover how TransPerfect Life Sciences ensures compliance with regulatory standards, improves global reporting accuracy, and simplifies the translation of documents for pharmacovigilance and drug safety.

How did you hear about us?
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.